

ASX: ALA

Arovella Therapeutics Limited
ACN 090 987 250



ASX RELEASE

1 May 2024

Updated Share Trading Policy

Arovella Therapeutics Limited ACN 090 987 250 (**ALA** or **Company**), in accordance with Listing Rule 12.10, advises it has updated its Share Trading Policy, with effect from 26 April 2024.

A copy of the revised policy is attached.

Release authorised by the Managing Director and Chief Executive Officer of Arovella Therapeutics Limited.

Dr Michael Baker
Chief Executive Officer & Managing Director
Arovella Therapeutics Limited
Tel +61 (0) 403 468 187
investor@arovella.com

NOTES TO EDITORS:**About Arovella Therapeutics Ltd**

Arovella Therapeutics Ltd (ASX: ALA) is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumours. Arovella's lead product is ALA-101. ALA-101 consists of CAR19-iNKT cells that have been modified to produce a Chimeric Antigen Receptor (CAR) that targets CD19. CD19 is an antigen found on the surface of numerous cancer types. Arovella is also expanding into solid tumour treatment through its CLDN18.2-targeting technology licensed from Sparx Group. iNKT cells also contain an invariant T cell receptor (iTCR) that targets α -GalCer bound CD1d, another antigen found on the surface of several cancer types. ALA-101 is being developed as an allogeneic cell therapy, which means it can be given from a healthy donor to a patient.

Glossary: **iNKT cell** – invariant Natural Killer T cells; **CAR** – Chimeric Antigen Receptor that can be introduced into immune cells to target cancer cells; **TCR** – T cell receptors are a group of proteins found on immune cells that recognise fragments of antigens as peptides bound to MHC complexes; **B-cell lymphoma** – A type of cancer that forms in B cells (a type of immune system cell); **CD1d** – Cluster of differentiation 1, which is expressed on some immune cells and cancer cells; **α GalCer** – alpha-galactosylceramide is a specific ligand for human and mouse natural killer T cells. It is a synthetic glycolipid.

For more information, visit www.arovella.com

SHARE TRADING POLICY

1. GENERAL

The Board of Arovella Therapeutics Ltd (Arovella) has reviewed and amended its Securities Trading Policy to comply with the new ASX Listing Rules and Guidance Note 27 (30 Jan 2015).

The Corporations Act contains provisions that prohibit a person in possession of material, non-public information relating to a Company over the company's securities by third parties.

The Share Trading Policy provides guidelines designed to prevent Arovella's Key Management Personnel as defined in accordance with AASB124, as those persons having authority and responsibility for planning, directing and controlling the activities of Arovella, directly or indirectly, including any Director (whether Executive or otherwise) of Arovella, (collectively called "Key Management Personnel (KMPs) for the purposes of this Policy) breaching these provisions.

2. INSIDER TRADING

Insider trading is the practice of dealing in a company's securities (which includes shares and options) by a person in possession of information not generally available and that if it was available would be likely to influence a person's decision to transact in the company's securities. It may also include the passing on of this information to another or procuring another person to deal in the securities.

KMPs of the Company must not, in their own capacity, or by a close family member, or as an agent for another, subscribe for, purchase or sell, or enter into an agreement to subscribe for, purchase or sell, any securities in the Company, or procure another person to do so, if that KMP possesses information that a reasonable person would expect to have a material effect on the price or value of the securities or influence a person's decision to buy or sell the securities in the Company if the information was generally available.

3. RESTRICTIONS ON KMPs DEALING IN AROVELLA SHARES

KMPs and their related parties are prohibited from dealing in Arovella securities during any Prohibited Period, which includes:

- a) Any "closed period";
"Closed Period" is defined as:
 - i. the 24-hour period before and after the release of price sensitive information; and
 - ii. the period from quarter end until the release of Arovella's quarterly cash flow report.
 - iii. The period from end of half year and full year until 1 week after the release of the financial results for the half year and full year respectively.

Further trading restrictions are defined as:

- b) No short-term share trading (i.e. shares purchased with the intention of short-term speculative gain);
- c) No transactions in Arovella securities while in the possession of inside information.
KMPs will normally be permitted to trade in the Company's securities provided that:
The trading is not likely to be seen by the public, press, other Shareholders or the Australian Securities Exchange (ASX) to be unfair or inappropriate. Examples of such trading include:

- i. transfers of securities already held in a superannuation fund or other saving scheme in which the KMP is a beneficiary;
- ii. an investment in, or trading in units of, a fund or other scheme (other than a scheme only investing in the Company's securities) where the assets of the fund or other scheme are invested at the discretion of a third party;
- iii. where the KMP is a trustee, trading in the Company's securities by that trust provided the KMP is not a beneficiary of the trust and any decision to trade during a Prohibited Period outside a Trading Window is taken by the other trustees or by the investment managers independently of the KMPs;
- iv. undertakings to accept, or the acceptance of, a takeover offer;
- v. Trading under an offer or invitation made to all or most of the security holders such as: a rights issue, a share purchase plan, a dividend or distribution reinvestment plan and an equal access buy-back, where the plan that determines the timing and structure of the offer has been approved by the Board. This includes decisions relating to whether or not to take-up the entitlements and the sale of entitlements required to provide for the take-up of the balance of entitlements under a renounceable pro rata issue;
- vi. a disposal of securities that is the result of a secured lender exercising their rights, for example, under a margin lending arrangement;
- vii. the exercise (but not the sale of securities following the exercise) of an option or right under an employee incentive scheme, or the conversion of a convertible security, where the final date for the exercise of the option or right, or the conversion of the security, falls during a Prohibited Period and the Company has been in an exceptionally long Prohibited Period or the Company has had a number of consecutive Prohibited Periods and the KMP could not reasonably have been expected to exercise it at a time when free to do so;
- viii. the exercise (but not the sale of securities following the exercise) of an option or right under an employee incentive scheme, or the conversion of a convertible security, where the final date for the exercise of the option or right, or the conversion of the security, falls outside of a Trading Window and the KMP could not reasonably have been expected to exercise it at a time when free to do so;
- ix. trading under a non-discretionary trading plan for which prior written clearance has been provided in accordance with procedures set out in the trading policy and where: (a) the KMP did not enter into the plan or amend the plan during a Prohibited Period outside a Trading Window; and (b) the trading plan does not permit the KMP to exercise any influence or discretion over how, when, or whether to trade.

NOTE: Even if the trading is excluded from this Policy, KMPs must not trade in the Company's securities if they are in possession of inside information.

4. EXEMPTION TO TRADE DURING CLOSED PERIODS

In exceptional circumstances trading may be permitted in a closed period, providing the individual involved is not in possession of price sensitive information, and only with prior written clearance. Prior written clearance must be obtained from either the Chairman of the Board or CEO. If being sought by the Chairman, written clearance must be obtained from either a Non-Executive Director or CEO.

Examples that may be subject to exemption are:

- a) A tax liability of such a person would not normally constitute severe financial hardship unless the person has no other means of satisfying the liability. A tax liability relating to securities received under an employee incentive scheme would also not normally constitute severe financial hardship or otherwise be considered an exceptional circumstance for the purpose of obtaining prior written clearance to sell or otherwise dispose of securities during a prohibited period. A copy of the request for written clearance must also be provided to the Company Secretary to ensure they are aware of the request and are able to communicate the request to the Board.
- b) An entity may consider it an exceptional circumstance if the person is required by a court order, or there are court enforceable undertakings, for example, in a bona fide family settlement, to transfer or sell the securities of the entity or there is some other overriding legal or regulatory requirement for him or her to do so.
- c) The determination of whether the person in question is in severe financial hardship or whether a particular set of circumstances falls within the range of exceptional circumstances identified in this policy can only be made by the designated officer(s) under the policy for this purpose. In recognition of the case that exceptional circumstances, by their nature, cannot always be specified in advance, it is envisaged that there may be other circumstances, which have not been identified in this policy, that may be deemed exceptional by the Chairman or the Chief Executive Officer and whereby prior written clearance is granted to permit trading. The person seeking clearance to trade must satisfy the designated officer(s) that they are in severe financial hardship or that their circumstances are otherwise exceptional and that the proposed sale or disposal of the relevant securities is the only reasonable course of action available.
- d) An acquisition of securities under a pro-rata issue
- e) An acquisition of securities under an employee incentive scheme.

5. DIRECTORS TO NOTIFY ASX OF SHAREHOLDING

ASX Listing Rule 3.19B requires Arovella to make arrangements with each Director to ensure that the Director discloses to Arovella all the information that Arovella requires for it to satisfy its obligations to advise ASX of notifiable interests of Directors. The Company Secretary with the information provided in clause 12 will as required by ASX Listing Rules 3.19A file a 3Y “Change of Director’s Interest Notices” within five (5) business days of a Director acquiring or disposing of the relevant interest.

6. REQUEST TO TRADE

To avoid any uncertainty related to the buy and sell of Arovella’s securities, all KMPs need to notify either the Chairman or the CEO/Managing Director, with a copy to the Company Secretary, identifying their intention to buy or sell (Request). The Chairman or the CEO/Managing Director needs to consider the request and respond within 24 hours of such a request. The response will either confirm that the request does not breach the Share trading Policy or, if in the opinion of the Chairman or CEO/Managing Director, the request does breach then an explanation needs to accompany the response. The KMP may provide a further justification to the request to trade based on exemptions under this policy.

All requests to buy or sell Arovella's securities as referred to in paragraph 6 must include the intended volume of securities to be purchased or sold and the expected time frame for the sale or purchase of Arovella's securities. Any approval to trade given by either the Chairman or the CEO/Managing Director automatically lapses after five 5 business days, after which time the KMP will need to re-submit a new request to trade under paragraph 6.

Before the Chairman is to engage in any trade involving the Company's securities, he or she must formally notify the Board about their intention to trade, specifying details including the anticipated date and quantity of securities involved, and whether they plan to sell or buy. The Chairman must also provide written confirmation they possess no inside information. The Chairman must receive written consent from the Board confirming there are no obstacles to the trade. The intention to trade and the authorisation will be recorded at the Company's next board meeting. The Chairman must adhere to any conditions imposed by the Board, including time restrictions related to the clearance.

7. DISCLOSURE

In order to maintain transparency, this policy is to be made publicly available via the Company's website www.arovella.com.

8. BREACHES OF POLICY

Any breaches of this policy will be severely dealt with and may lead to immediate termination.

(Approved by the Board effective 26 April 2024)